Nils Lonberg, Ph.D. has served as a member of our board of directors since April 2019 and was previously the Chairperson of our board of directors until August 2024. Since June 2025, Dr. Lonberg has served as Chief Executive Officer of Tripeaks Therapeutics, Inc., a biotechnology company. Dr. Lonberg also currently serves as an Executive in Residence at Canaan Partners, a venture capital firm, where he has been employed since May 2019 and where he focuses on investments in life science companies. Prior to Canaan Partners, Dr. Lonberg served as Vice President, Oncology Discovery Biology, at Bristol-Myers Squibb Co., a biopharmaceutical company, where he led drug discovery efforts for both targeted and immuno-oncology agents, from September 2009 to April 2019. Dr. Lonberg also serves on the boards of directors of various private companies. Dr. Lonberg received his Ph.D. in Biochemistry and Molecular Biology from Harvard University and a B.S. in chemistry from Reed College. He was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and was elected to the National Academy of Engineering in 2015. We believe Dr. Lonberg s extensive executive, managerial and business experience with life sciences companies qualifies him to serve on our board of directors.